Publications by authors named "S Weitsman"
Article Synopsis
- Rifaximin is FDA-approved for treating IBS-D but has limited effectiveness due to poor solubility impacting its ability to target E. coli in the mucus layer.
- Adding N-acetylcysteine (NAC) enhances rifaximin's efficacy against E. coli, as shown through tests in both lab assays and a rat model of IBS-D.
- The combination of rifaximin and NAC effectively normalized stool consistency and bacterial levels in the rat model, suggesting potential for improved treatment responses in IBS-D patients.
Article Synopsis
- * Specific microbial features were identified for overweight and obese subjects, such as changes in the abundance of key bacteria like Bifidobacterium and Lactobacillus, indicating their potential roles in metabolic health.
- * The study revealed both progressive (escalation) and reverse (de-escalation) changes in microbial populations as subjects transitioned from normal weight to overweight and then to obesity, suggesting complex interactions between gut bacteria and metabolic conditions.
Studies using stool samples suggest that non-sugar sweetener (NSS) consumption affects gut microbiome composition. However, stool does not represent the entire gut. We analyzed the duodenal luminal microbiome in subjects consuming non-aspartame non-sugar sweeteners (NANS, N = 35), aspartame only (ASP, N = 9), and controls (CON, N = 55) and the stool microbiome in a subset (N = 40).
View Article and Find Full Text PDFDiarrhea-predominant irritable bowel syndrome (IBS-D), associated with increased intestinal permeability, inflammation, and small intestinal bacterial overgrowth, can be triggered by acute gastroenteritis. Cytolethal distending toxin B (CdtB) is produced by gastroenteritis-causing pathogens and may underlie IBS-D development, through molecular mimicry with vinculin. Here, we examine the effects of exposure to CdtB alone on gut microbiome composition, host intestinal gene expression, and IBS-D-like phenotypes in a rat model.
View Article and Find Full Text PDFBackground: We recently demonstrated that diarrhea-predominant irritable bowel syndrome (IBS-D) subjects have higher relative abundance (RA) of hydrogen sulfide (HS)-producing Fusobacterium and Desulfovibrio species, and constipation-predominant IBS (IBS-C) subjects have higher RA of methanogen Methanobrevibacter smithii.
Aims: In this study, we investigate the effects of increased methanogens or HS producers on stool phenotypes in rat models.
Methods: Adult Sprague-Dawley rats were fed high-fat diet (HFD) for 60 days to increase M.